Benzinga

DECEMBER 27, 2023

In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE: BMY ) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB ) for $62.50

Alpha 69

Alpha Equity 69

Benzinga

APRIL 29, 2022

Bristol Myers' Oral Heart Disease Drug Scores FDA Approval. The FDA has approved Bristol Myers Squibb & Co's (NYSE: BMY ) Camzyos (mavacamten) for obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. Stocks In Focus. Zymeworks Confirms $10.50/Share

98

98

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice. Let’s dig in.

Marketability 40

Marketability Finance Equity Debt Financing 40

Reynolds Holding

OCTOBER 5, 2022

Lucia Companies, Inc. In Lee Enterprises , a beneficial owner of the company sought to nominate several directors as part of a takeover attempt, but it failed to comply with unambiguous advance notice bylaws requiring it to become a record holder and submit the company’s nominee questionnaire forms before the nomination deadline.

Start-ups 72

Start-ups Marketability Equity Compliance 72